Christopher Knute O'Brien

US Patent:

20030224019, Dec 4, 2003

Filed:

Feb 27, 2003

Appl. No.:

10/378042

Inventors:

Christopher O'Brien - San Diego CA, US

International Classification:

A61K039/08

US Classification:

424/239100

Abstract:

Methods of treating nerve entrapment syndromes and/or the pain associated with nerve entrapment syndromes using botulinum type B toxin are disclosed. These methods involve, for example, injections of botulinum type B toxin to the tissue impinging on the nerve and/or the interstitial area around the nerve and/or the connective tissue surrounding the nerve.

US Patent:

20080171065, Jul 17, 2008

Filed:

Mar 26, 2008

Appl. No.:

12/056096

Inventors:

Christopher O'Brien - San Diego CA, US

International Classification:

A61K 39/08

US Classification:

4242391

Abstract:

Methods of treating nerve entrapment syndromes and/or the pain associated with nerve entrapment syndromes using type B toxin are disclosed. These methods involve, for example, injections of type B toxin to the tissue impinging on the nerve and/or the interstitial area around the nerve and/or the connective tissue surrounding the nerve.

US Patent:

20190015396, Jan 17, 2019

Filed:

Jun 23, 2016

Appl. No.:

15/738537

Inventors:

- San Diego CA, US
Christopher F. O'BRIEN - San Diego CA, US

International Classification:

A61K 31/437
A61P 25/18
A61K 9/20

Abstract:

Methods are provided herein for treating agitation in a subject who has Alzheimer's disease comprising administering a VMAT2 inhibitor to a subject in need thereof. VMAT2 inhibitors useful in the methods provided herein include tetrabenazine and (S)-2-Amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.

US Patent:

20170071932, Mar 16, 2017

Filed:

May 6, 2015

Appl. No.:

15/309108

Inventors:

- San Diego CA, US
Christopher F. O'Brien - San Diego CA, US

International Classification:

A61K 31/4745

Abstract:

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)α-HTBZ) is used in the methods described herein for treating a subject in need thereof.

US Patent:

20160034008, Feb 4, 2016

Filed:

Aug 3, 2015

Appl. No.:

14/817106

Inventors:

- Palo Alto CA, US
Christopher Dana O'Brien - San Diego CA, US

Assignee:

RADX Technologies, Inc. - Palo Alto CA

International Classification:

G06F 1/20
H05K 13/04

Abstract:

This invention relates generally to modular instrument chassis and more particularly to benchtop and rack mount modular instrument chassis that employ the PXI and PXIe standards. The present invention combines the benefits of the PXI/PXIe systems without the drawbacks that preclude PXI/PXIe systems from being used effectively in a deployable environment. Embodiments of the present invention enable PXI/PXIe systems to be deployed in a benchtop or rack mount deployable environment and enable front-to-back cooling, flexible I/O (front and back I/O panels), consistent I/O on front and back panels for reproducible and repeatable connections to external devices and for calibration requirements associated with such environments while maintaining the modularity benefits of PXI/PXIe and without sacrificing PXI/PXIe slots.

US Patent:

20140151704, Jun 5, 2014

Filed:

Mar 14, 2013

Appl. No.:

13/831067

Inventors:

Peregrine Semiconductor Corporation - , US
Michael McCafferty - San Diego CA, US
Alain Duvallet - San Diego CA, US
Masaki Sato - San Diego CA, US
Christopher O'Brien - San Diego CA, US
Anthony Mark Miscione - Ramona CA, US
George Imthurn - San Diego CA, US

Assignee:

PEREGRINE SEMICONDUCTOR CORPORATION - San Diego CA

International Classification:

H01L 21/322
H01L 29/36

US Classification:

257 49, 438476

Abstract:

Embodiments of preparing substrates for subsequent bonding with semiconductor layer are described herein. A substrate may be prepared with one or more chemicals or a sacrificial layer to limit or remove substrate contaminants and reduce substrate surface damage. Other embodiments may be described and claimed.